Unconfirmed: Facebook may soon file IPO

Juan Martinez, senior editor, Direct Marketing News
Juan Martinez, senior editor, Direct Marketing News

Facebook is preparing to file papers for an initial public offering (IPO), The Wall Street Journal reported on Jan. 28. The outlet reported that “people familiar with the matter,” say the IPO could come as soon as Jan. 31 and that Facebook is close to picking Morgan Stanley to lead the deal. Facebook declined to provide comment to Direct Marketing News when asked if the report was accurate. No confirmed reports have surfaced elsewhere.

Facebook's silence on the matter has led to much juicy speculation.

Bloomberg Businessweek has “two people” on the record saying Facebook's valuation is between $75-$100 billion.

Forbes says the valuation is overblown and that the IPO will be irrelevant because it won't unleash corporate capital spending or boost the overall venture financing market.

CNBC financial analyst Jim Cramer says a $70 billion valuation is a good deal for investors but “if it's priced at $110 billion, however, he doesn't think it will make that much money,” according to a CNBC post on Cramer's assessment.

Even Rupert Murdoch threw a jab at the valuation, tweeting, “Facebook [is] a brilliant achievement, but $75-100bn? Would make Apple look really cheap.”

Regardless of the ultimate financial outcome of the IPO, any additional capital should mean major opportunities for marketers, as Facebook would certainly invest heavily in driving additional advertising and advertising services revenue wherever possible.

Stay tuned to Direct Marketing News for additional coverage of the IPO as more information surfaces.

You must be a registered member of Direct Marketing News to post a comment.

Sign up to our newsletters

Latest Jobs:


Company of the Week


SK&A is a leading provider of U.S. healthcare information solutions and databases. As part of IMS Health, SK&A researches and maintains contact and profiling data for over 2 million healthcare providers, including 800,000+ prescribers. SK&A's data supports research and marketing initiatives for life sciences, medical device, managed healthcare, direct marketing, publishing, education and more. SK&A's proprietary databases are telephone-verified twice per year from its world class Research Centers. SK&A enables multi-channel marketing and sets the standard for data quality and reliability. SK&A's customers include many of America's most recognized healthcare, publishing and pharmaceutical institutions.


Featured Listings

SKA

SKA

SK&A is a leading provider of U.S. healthcare information solutions and databases. As ...